Compare Amphastar Pharmaceuticals Inc (AMPH) vs Nasdaq100 ETF (QQQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Nasdaq100 ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Nasdaq100 ETF trades at $718.92. The key difference: Nasdaq100 ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | QQQ | |
|---|---|---|
Market Cap | $826.08M | — |
Sector | Health | — |
52-Week High | $30.81 | $746.16 |
52-Week Low | $16.87 | $553.88 |
Enterprise Value | $1.22B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
QQQ trades at $725.54, up 0.32% with a bullish technical signal from moving averages. Support lies at $718 and resistance at $727. The ETF faces new competition from BlackRock's IQQ but maintains strong Nasdaq-100 exposure. Recent news highlights its role in growth portfolios and hedging strategies using SQQQ.
Outlook remains mixed with 50% analyst buy ratings. Key risks include market volatility and competitive ETF launches. Upside potential hinges on tech sector performance, while downside protection strategies are gaining attention among investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →
